Developer docs
API playgroundTry for free, no card

Search company profiles

Aardvark Therapeutics

Full company profile

uuid00005jo

Namestring
Aardvark Therapeutics
Legal namestring
Aardvark Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2017 by Dr. Tien Lee, MD, headquartered in San Diego, California, and listed on NASDAQ under ticker AARD following its 2025 IPO. The company develops oral small-molecule therapies that activate bitter taste receptors (TAS2Rs) expressed on enteroendocrine cells in the gut lumen, triggering local release of satiety hormones (CCK and GLP-1) that engage gut-brain vagal signaling to suppress hunger. Its lead compound ARD-101 is restricted primarily to the digestive tract with approximately 1% systemic exposure, a design intended to minimize off-target toxicities relative to systemic CCK analogues.

The pipeline is built around ARD-101, which has received FDA Orphan Drug Designation and is being evaluated in the Phase 3 HERO trial for hyperphagia in Prader-Willi Syndrome (with development also directed at Hypothalamic Obesity). ARD-201 extends the platform into general obesity as an oral once-daily fixed-dose combination of ARD-101 with a DPP-4 inhibitor (POWER trial for weight maintenance, STRENGTH trial for weight loss). Earlier-stage assets include WE-868 (metabolic/obesity) and DIA-615, a topical candidate for inflammatory skin diseases such as psoriasis that was placed in the newly formed wholly-owned US subsidiary Ardia Therapeutics in February 2026. Phase 3 HERO enrollment was expanded in late 2025 to sites in the US, Australia, Canada, and the UK.

Aardvark has no approved products and no commercial revenue, making it pre-revenue with a business model contingent on future commercialization through specialty drug sales and/or licensing royalties once regulatory approval is secured. The company has raised approximately $129 million in venture funding across its Series B (Sorrento-led, $29M in 2021) and Series C (Decheng Capital-led, $85M in 2024) prior to listing. Its clinical programs have been materially disrupted in 2026 by a voluntary pause of the Phase 3 HERO trial in February 2026 and a subsequent FDA full clinical hold on the ARD-101 IND in May 2026, both tied to reversible cardiac safety signals, with related securities-fraud investigations now underway.

Short descriptiontext

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecules that activate gut bitter taste receptors (TAS2Rs) to suppress hunger, targeting rare metabolic disorders and obesity. Its lead candidate ARD-101 is under an FDA clinical hold following cardiac safety signals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
obesity therapeutics, metabolic disease drugs, small molecule therapies, rare disease treatments, clinical stage biopharmaceutical
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Obesity and Metabolic Disease Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1None — Pre-Revenue Clinical Stage
TypeLicensing Royalties
Description

Aardvark Therapeutics is a clinical-stage biopharmaceutical company with no approved products and no current revenue. The company reported a net loss of $57.6 million for full-year 2025 and $21.6 million for Q1 2026, with R&D expenses of $48.9 million in 2025. Future revenue is expected to come from commercialization of ARD-101, ARD-201, and other pipeline assets (likely a mix of specialty drug sales and potential partnership/licensing income) once regulatory approval is obtained.

biospace.com
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Ardia Therapeutics
Description

Wholly-owned U.S. subsidiary developing the dermatology pipeline led by DIA-615, a topical treatment for inflammatory skin diseases including psoriasis.

globenewswire.com
Core offering1 text field

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies that activate bitter taste receptors (TAS2Rs) on enteroendocrine cells in the gut to trigger local release of satiety hormones (CCK and GLP-1), activating gut-brain signaling that suppresses hunger. Its lead candidate ARD-101 is gut-restricted (~1% systemic exposure) and is in development for hyperphagia in Prader-Willi Syndrome (HERO Phase 3) and Hypothalamic Obesity, while ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, targets obesity and weight maintenance. Additional pipeline assets include WE-868 in metabolic disease and DIA-615 in dermatology (inflammatory skin diseases).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aardvark Therapeutics operates a clinical-stage biopharmaceutical pipeline rather than a unified commercial software platform. Its portfolio centers on proprietary, orally delivered small molecules that activate bitter taste receptors (TAS2Rs) in the gut to trigger satiety hormone release and suppress hunger. The lead asset ARD-101 anchors the pipeline and is being studied in the HERO Phase 3 trial for hyperphagia in Prader-Willi Syndrome, with additional development in Hypothalamic Obesity. ARD-201 extends this approach into obesity as an oral once-daily fixed-dose combination of ARD-101 with a DPP-4 inhibitor (POWER trial for weight maintenance; STRENGTH trial for weight loss). Earlier-stage pipeline assets WE-868 (metabolic/obesity) and DIA-615 (a topical dermatology candidate for inflammatory skin diseases such as psoriasis, housed in the newly formed subsidiary Ardia Therapeutics) round out the company's portfolio of hunger- and inflammation-associated programs.

Product and service4 records
1ARD-101
CategoryInvestigational small-molecule drug candidate (lead asset, metabolic disease)
Description

Oral, gut-restricted investigational small-molecule TAS2R agonist that activates bitter taste receptors on enteroendocrine cells in the gut, triggering local release of satiety hormones (CCK and GLP-1) and gut-brain signaling to suppress hunger. Lead indication is hyperphagia in Prader-Willi Syndrome (Phase 3 HERO trial); also in development for Hypothalamic Obesity. Approximately 1% systemic exposure, designed to minimize off-target toxicity. FDA Orphan Drug Designation granted.

2ARD-201
CategoryInvestigational small-molecule combination drug candidate (obesity/weight maintenance)
Description

Investigational, fixed-dose once-daily oral combination of ARD-101 with a DPP-4 inhibitor, being developed for obesity and obesity-related conditions. POWER trial evaluates weight maintenance after GLP-1 discontinuation; STRENGTH trial combines sitagliptin with TAS2R agonism for weight loss.

3WE-868
CategoryInvestigational small-molecule drug candidate (metabolic disease pipeline)
Description

Pipeline compound within Aardvark's metabolic/obesity portfolio, advancing in clinical development for obesity and metabolic diseases and referenced alongside ARD-101 and ARD-201 in ObesityWeek 2025 presentations.

4DIA-615
CategoryInvestigational topical drug candidate (dermatology pipeline, in subsidiary Ardia Therapeutics)
Description

Lead asset of Ardia Therapeutics, Aardvark's wholly-owned U.S. dermatology subsidiary; a topical small-molecule treatment being developed for inflammatory skin diseases including psoriasis, planned to enter clinical development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Soleno Therapeutics is developing DCCR (diazoxide choline controlled-release) for hyperphagia in Prader-Willi Syndrome, the same lead indication as Aardvark's ARD-101, making it the most direct head-to-head competitor in PWS.

TypeDirect peer
Description

Rhythm Pharmaceuticals markets setmelanotide (IMCIVREE) for several rare obesity disorders including BBS and is pursuing PWS; it is the established rare-obesity player that Aardvark would compete with across its lead and follow-on rare metabolic indications.

TypeDirect peer
Description

Viking Therapeutics is a clinical-stage biopharma developing oral and injectable obesity therapies (e.g., VK2735), competing with Aardvark in the broader obesity treatment race and sharing the small-cap clinical-stage biotech profile.

TypeDirect peer
Description

Structure Therapeutics is developing oral GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and type 2 diabetes, making it a direct competitor to Aardvark's oral, gut-restricted obesity strategy.

TypeDirect peer
Description

Terns Pharmaceuticals is a clinical-stage company developing oral obesity therapies including TERN-601, a small-molecule GLP-1 agonist, putting it in direct competition with Aardvark's oral obesity positioning.

TypeBroad incumbent
Description

Eli Lilly markets Mounjaro/Zepbound (tirzepatide) and has a deep oral obesity pipeline, setting the dominant standard of care that Aardvark's oral, hunger-focused approach must differentiate against.

TypeBroad incumbent
Description

Novo Nordisk markets Ozempic/Wegovy (semaglutide) and is advancing oral semaglutide, making it the incumbent GLP-1 leader whose scale, manufacturing, and reimbursement reach define the competitive ceiling for Aardvark's obesity ambitions.

TypeEmerging player
Description

Rivus Pharmaceuticals is developing controlled metabolic accelerators (e.g., HU6) for obesity and metabolic disease, representing a parallel small-molecule, mechanism-distinct approach to Aardvark's TAS2R platform.

TypeEmerging player
Description

Keros Therapeutics is a clinical-stage biotech developing therapeutics for hematological and musculoskeletal disorders with metabolic components, sharing the small-cap clinical-stage profile and similar investor base as Aardvark.

TypeEmerging player
Description

Lexicon Pharmaceuticals is developing small-molecule drug candidates in diabetes, metabolism, and pain, overlapping with Aardvark in metabolic disease R&D and representing a comparable small-cap clinical-stage peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aardvark Therapeutics

Obesity and Metabolic Disease Therapeuticsaardvarktherapeutics.com

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecules that activate gut bitter taste receptors (TAS2Rs) to suppress hunger, targeting rare metabolic disorders and obesity. Its lead candidate ARD-101 is under an FDA clinical hold following cardiac safety signals.

What Aardvark Therapeutics does

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2017 by Dr. Tien Lee, MD, headquartered in San Diego, California, and listed on NASDAQ under ticker AARD following its 2025 IPO. The company develops oral small-molecule therapies that activate bitter taste receptors (TAS2Rs) expressed on enteroendocrine cells in the gut lumen, triggering local release of satiety hormones (CCK and GLP-1) that engage gut-brain vagal signaling to suppress hunger. Its lead compound ARD-101 is restricted primarily to the digestive tract with approximately 1% systemic exposure, a design intended to minimize off-target toxicities relative to systemic CCK analogues.

The pipeline is built around ARD-101, which has received FDA Orphan Drug Designation and is being evaluated in the Phase 3 HERO trial for hyperphagia in Prader-Willi Syndrome (with development also directed at Hypothalamic Obesity). ARD-201 extends the platform into general obesity as an oral once-daily fixed-dose combination of ARD-101 with a DPP-4 inhibitor (POWER trial for weight maintenance, STRENGTH trial for weight loss). Earlier-stage assets include WE-868 (metabolic/obesity) and DIA-615, a topical candidate for inflammatory skin diseases such as psoriasis that was placed in the newly formed wholly-owned US subsidiary Ardia Therapeutics in February 2026. Phase 3 HERO enrollment was expanded in late 2025 to sites in the US, Australia, Canada, and the UK.

Aardvark has no approved products and no commercial revenue, making it pre-revenue with a business model contingent on future commercialization through specialty drug sales and/or licensing royalties once regulatory approval is secured. The company has raised approximately $129 million in venture funding across its Series B (Sorrento-led, $29M in 2021) and Series C (Decheng Capital-led, $85M in 2024) prior to listing. Its clinical programs have been materially disrupted in 2026 by a voluntary pause of the Phase 3 HERO trial in February 2026 and a subsequent FDA full clinical hold on the ARD-101 IND in May 2026, both tied to reversible cardiac safety signals, with related securities-fraud investigations now underway.

Aardvark Therapeutics firmographics

Firmographics
Name
Aardvark Therapeutics
Legal name
Aardvark Therapeutics, Inc.
Website
https://aardvarktherapeutics.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecules that activate gut bitter taste receptors (TAS2Rs) to suppress hunger, targeting rare metabolic disorders and obesity. Its lead candidate ARD-101 is under an FDA clinical hold following cardiac safety signals.
Ownership category
akta.pro rank

Aardvark Therapeutics industry classification

Industry
Product category
Obesity and Metabolic Disease Therapeutics
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Obesity therapeutics
  • Metabolic disease drugs
  • Small molecule therapies
  • Rare disease treatments
  • Clinical stage biopharmaceutical

Where Aardvark Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Aardvark Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. None — Pre-Revenue Clinical Stage: Aardvark Therapeutics is a clinical-stage biopharmaceutical company with no approved products and no current revenue. The company reported a net loss of $57.6 million for full-year 2025 and $21.6 million for Q1 2026, with R&D expenses of $48.9 million in 2025. Future revenue is expected to come from commercialization of ARD-101, ARD-201, and other pipeline assets (likely a mix of specialty drug sales and potential partnership/licensing income) once regulatory approval is obtained.

Go-to-market motion1 record

Aardvark Therapeutics product offering

Product offering

Core offering

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies that activate bitter taste receptors (TAS2Rs) on enteroendocrine cells in the gut to trigger local release of satiety hormones (CCK and GLP-1), activating gut-brain signaling that suppresses hunger. Its lead candidate ARD-101 is gut-restricted (~1% systemic exposure) and is in development for hyperphagia in Prader-Willi Syndrome (HERO Phase 3) and Hypothalamic Obesity, while ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, targets obesity and weight maintenance. Additional pipeline assets include WE-868 in metabolic disease and DIA-615 in dermatology (inflammatory skin diseases).

Product overview

Aardvark Therapeutics operates a clinical-stage biopharmaceutical pipeline rather than a unified commercial software platform. Its portfolio centers on proprietary, orally delivered small molecules that activate bitter taste receptors (TAS2Rs) in the gut to trigger satiety hormone release and suppress hunger. The lead asset ARD-101 anchors the pipeline and is being studied in the HERO Phase 3 trial for hyperphagia in Prader-Willi Syndrome, with additional development in Hypothalamic Obesity. ARD-201 extends this approach into obesity as an oral once-daily fixed-dose combination of ARD-101 with a DPP-4 inhibitor (POWER trial for weight maintenance; STRENGTH trial for weight loss). Earlier-stage pipeline assets WE-868 (metabolic/obesity) and DIA-615 (a topical dermatology candidate for inflammatory skin diseases such as psoriasis, housed in the newly formed subsidiary Ardia Therapeutics) round out the company's portfolio of hunger- and inflammation-associated programs.

Differentiator

Problem solved

Functional benefit

Brands

  • Ardia Therapeutics: Wholly-owned U.S. subsidiary developing the dermatology pipeline led by DIA-615, a topical treatment for inflammatory skin diseases including psoriasis.

Products and services

  • ARD-101 Oral, gut-restricted investigational small-molecule TAS2R agonist that activates bitter taste receptors on enteroendocrine cells in the gut, triggering local release of satiety hormones (CCK and GLP-1) and gut-brain signaling to suppress hunger. Lead indication is hyperphagia in Prader-Willi Syndrome (Phase 3 HERO trial); also in development for Hypothalamic Obesity. Approximately 1% systemic exposure, designed to minimize off-target toxicity. FDA Orphan Drug Designation granted.
  • ARD-201 Investigational, fixed-dose once-daily oral combination of ARD-101 with a DPP-4 inhibitor, being developed for obesity and obesity-related conditions. POWER trial evaluates weight maintenance after GLP-1 discontinuation; STRENGTH trial combines sitagliptin with TAS2R agonism for weight loss.
  • WE-868 Pipeline compound within Aardvark's metabolic/obesity portfolio, advancing in clinical development for obesity and metabolic diseases and referenced alongside ARD-101 and ARD-201 in ObesityWeek 2025 presentations.
  • DIA-615 Lead asset of Ardia Therapeutics, Aardvark's wholly-owned U.S. dermatology subsidiary; a topical small-molecule treatment being developed for inflammatory skin diseases including psoriasis, planned to enter clinical development.

Companies that use Aardvark Therapeutics

Customer profile

Ideal customer profiles1 record

Aardvark Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aardvark Therapeutics partnerships and signals

Strategic signal

Recent moves8 records

Expansion highlights6 records

Aardvark Therapeutics competitors and assessment

Company assessment

Direct peers

  • Soleno Therapeutics: Soleno Therapeutics is developing DCCR (diazoxide choline controlled-release) for hyperphagia in Prader-Willi Syndrome, the same lead indication as Aardvark's ARD-101, making it the most direct head-to-head competitor in PWS.
  • Rhythm Pharmaceuticals: Rhythm Pharmaceuticals markets setmelanotide (IMCIVREE) for several rare obesity disorders including BBS and is pursuing PWS; it is the established rare-obesity player that Aardvark would compete with across its lead and follow-on rare metabolic indications.
  • Viking Therapeutics: Viking Therapeutics is a clinical-stage biopharma developing oral and injectable obesity therapies (e.g., VK2735), competing with Aardvark in the broader obesity treatment race and sharing the small-cap clinical-stage biotech profile.
  • Structure Therapeutics: Structure Therapeutics is developing oral GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and type 2 diabetes, making it a direct competitor to Aardvark's oral, gut-restricted obesity strategy.
  • Terns Pharmaceuticals: Terns Pharmaceuticals is a clinical-stage company developing oral obesity therapies including TERN-601, a small-molecule GLP-1 agonist, putting it in direct competition with Aardvark's oral obesity positioning.

Broad incumbents

  • Eli Lilly: Eli Lilly markets Mounjaro/Zepbound (tirzepatide) and has a deep oral obesity pipeline, setting the dominant standard of care that Aardvark's oral, hunger-focused approach must differentiate against.
  • Novo Nordisk: Novo Nordisk markets Ozempic/Wegovy (semaglutide) and is advancing oral semaglutide, making it the incumbent GLP-1 leader whose scale, manufacturing, and reimbursement reach define the competitive ceiling for Aardvark's obesity ambitions.

Emerging players

  • Rivus Pharmaceuticals: Rivus Pharmaceuticals is developing controlled metabolic accelerators (e.g., HU6) for obesity and metabolic disease, representing a parallel small-molecule, mechanism-distinct approach to Aardvark's TAS2R platform.
  • Keros Therapeutics: Keros Therapeutics is a clinical-stage biotech developing therapeutics for hematological and musculoskeletal disorders with metabolic components, sharing the small-cap clinical-stage profile and similar investor base as Aardvark.
  • Lexicon Pharmaceuticals: Lexicon Pharmaceuticals is developing small-molecule drug candidates in diabetes, metabolism, and pain, overlapping with Aardvark in metabolic disease R&D and representing a comparable small-cap clinical-stage peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Aardvark Therapeutics social profiles

Digital presence

Aardvark Therapeutics compliance and trust

Trust signal

Compliance4 records

Aardvark Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aardvark Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Aardvark Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aardvark Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aardvark Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aardvark Therapeutics

What does Aardvark Therapeutics do?

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies that activate bitter taste receptors (TAS2Rs) on enteroendocrine cells in the gut to trigger local release of satiety hormones (CCK and GLP-1), activating gut-brain signaling that suppresses hunger. Its lead candidate ARD-101 is gut-restricted (~1% systemic exposure) and is in development for hyperphagia in Prader-Willi Syndrome (HERO Phase 3) and Hypothalamic Obesity, while ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, targets obesity and weight maintenance. Additional pipeline assets include WE-868 in metabolic disease and DIA-615 in dermatology (inflammatory skin diseases).

Is Aardvark Therapeutics a public or private company?

Aardvark Therapeutics is a public company. It is classified as public and is currently operating.

When was Aardvark Therapeutics founded?

Aardvark Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Aardvark Therapeutics based?

Aardvark Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Aardvark Therapeutics make money?

One revenue line is on record: none — Pre-Revenue Clinical Stage.

Who are Aardvark Therapeutics's main competitors?

Direct peers on record are Soleno Therapeutics, Rhythm Pharmaceuticals, Viking Therapeutics, Structure Therapeutics and Terns Pharmaceuticals. Broad incumbents are Eli Lilly and Novo Nordisk. Emerging players are Rivus Pharmaceuticals, Keros Therapeutics and Lexicon Pharmaceuticals.

Does Aardvark Therapeutics have an API?

No public API is recorded for Aardvark Therapeutics.

What industry is Aardvark Therapeutics in?

Aardvark Therapeutics's product category is Obesity and Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAardvark Therapeutics, Inc. Stock 12‑Month Price Target Cut to $3.5, Implies 250% UpsideAnalysts' average price target for Aardvark Therapeutics fell from $4 to $3.5, implying about 250% upside from the Nov. 19 close. The consensus remains Hold across 10 analysts, with 3 Buys, 5 Holds, and 2 Sells.TradingViewAardvark Reports Q3 2026 Net Loss of $19.2 Million, Cash of $60.3 MillionAardvark reported a Q3 2026 net loss of $19.2 million, up from $16.3 million a year earlier, with cash and short-term investments of $60.3 million. The FDA lifted the clinical hold on its ARD-101 trial for Prader-Willi Syndrome, and the company expects to resume clinical activities in 2027.Quiver QuantitativeAardvark Reports $19.2 Million Third-Quarter Net Loss as FDA Lifts ARD-101 Hold | AARD Stock NewsAardvark Therapeutics reported a Q3 2026 net loss of $19.2 million, or $0.88 per share, with R&D expenses of $15.7 million. The FDA lifted the clinical hold on ARD-101 for Prader-Willi syndrome, and the company expects to resume PWS clinical activities in 2027. Cash and short-term investments totaled $60.3 million as of September 30, 2026.Business & FinancialAttention Long-Term Shareholders Of Aardvark Therapeutics, Inc. (NASDAQ: AARD) Erasca, Inc. (NASDAQ: ERAS) Planet Fitness, Inc. (NYSE: PLNT) And PROCEPT Biorobotics Corporation (NASDAQ: PRCT): Grabar Law Office Is Investigating Claims On Your BehalfGrabar Law Office is investigating securities claims for Aardvark, Erasca, Planet Fitness, and Procept BioRobotics. Allegations include false statements about drug safety, undisclosed discount programs, and misleading growth projections, with some companies' stock declining after disclosures.GlobeNewswireAttention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your BehalfGrabar Law Office announced investigations into Aardvark, Erasca, Planet Fitness, and Procept BioRobotics, alleging securities fraud and fiduciary breaches. The claims involve false statements about drug safety, marketing, and undisclosed discount programs, with some companies' stock declining after disclosures.Business & FinancialPrader Willi Syndrome Clinical Trial Pipeline: Emerging Therapies And Key Developments Shaping The Treatment Landscape DelveinsightAardvark Therapeutics reported exploratory data from its terminated Phase III HERO trial for ARD-101, showing hyperphagia scores declined during dose escalation but returned toward baseline after discontinuation. DelveInsight's pipeline report covers 20+ companies and 20+ therapies, including Pitolisant, BMB-101, RM718, and CCT987.Business & FinancialAttention Long-Term Shareholders Of Aardvark Therapeutics, Inc. (NASDAQ: AARD) Erasca, Inc. (NASDAQ: ERAS) Insulet Corporation (NASDAQ: PODD) And Planet Fitness, Inc. (NYSE: PLNT): Grabar Law Office Is Investigating Claims On Your BehalfGrabar Law Office is investigating securities claims for Aardvark, Erasca, Insulet, and Planet Fitness shareholders. Allegations include false statements about drug safety, manufacturing defects, and marketing metrics, with some companies announcing voluntary pauses or corrections. Shareholders are urged to seek corporate reforms and damages.American Banking and Market NewsHC Wainwright Has Lowered Expectations for Aardvark Therapeutics (NASDAQ:AARD) Stock PriceHC Wainwright lowered its price target on Aardvark Therapeutics from $4.00 to $2.00, keeping a neutral rating. The stock opened at $1.30, with a consensus rating of Hold and an average price target of $11.28. Analysts expect the company to report -3.05 EPS for the current fiscal year.The future of tradingLifshitz Law PLLC Announces Investigations of UWM Holdings Corporation (NYSE: UWMC), The Simply Good Foods Company (NASDAQ: SMPL), Aardvark Therapeutics, Inc. (NASDAQ: AARD), and Floteck Industries, ILifshitz Law PLLC announced investigations into UWM Holdings, Simply Good Foods, Aardvark Therapeutics, and Floteck Industries for possible securities violations. Allegations include false statements about hedging, failed acquisitions, overstated drug safety, and project risks. Investors are directed to contact the firm for more information.Investing.comAardvark Therapeutics stock rating cut to Perform by OppenheimerOppenheimer downgraded Aardvark Therapeutics to Perform and withdrew its $21 price target, after the stock fell 63% to $0.98. The company lifted the clinical hold on ARD-101 and released exploratory data from the Phase 3 HERO study, with Oppenheimer citing cardiac safety concerns. Aardvark plans to seek FDA feedback on a revised Phase 3 design and resume clinical activities in 2027.